How does PTKF.Y's PE Ratio compare to its peers?

PTKF.Y is good value based on its Price-To-Earnings Ratio (19.1x) compared to the peer average (22x).

How does PTKF.Y's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

PTKF.Y is expensive based on its Price-To-Earnings Ratio (19.1x) compared to the US Pharmaceuticals industry average (16.7x).

What is PTKF.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate PTKF.Y's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of PTKF.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

PTKF.Y ($20.75) is trading above our estimate of [[fair value]] ($9.2)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

PTKF.Y Stock Overview

Develops, manufactures, and trades in pharmaceutical products in Indonesia. More details

PTKF.Y fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	5/6

Rewards

Earnings are forecast to grow 9.59% per year

Earnings have grown 4% per year over the past 5 years

Pays a reliable dividend of 2.43%

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

PT Kalbe Farma Tbk. Competitors

Prestige Consumer Healthcare

NYSE:PBH

US$3.9b

Organon

NYSE:OGN

US$3.8b

Corcept Therapeutics

NasdaqCM:CORT

US$5.4b

Elanco Animal Health

NYSE:ELAN

US$5.7b

Price History & Performance

Summary of share price highs, lows and changes for Kalbe Farma
Historical stock prices
Current Share Price	Rp20.75
52 Week High	Rp23.73
52 Week Low	Rp16.38
Beta	0.23
1 Month Change	4.06%
3 Month Change	-12.54%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-3.04%
Change since IPO	12.05%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PTKF.Y	US Pharmaceuticals	US Market
7D	0%	-1.5%	-2.4%
1Y	n/a	7.9%	23.4%

Return vs Industry: Insufficient data to determine how PTKF.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how PTKF.Y performed against the US Market.

Price Volatility

Is PTKF.Y's price volatile compared to industry and market?
PTKF.Y volatility
PTKF.Y Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PTKF.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PTKF.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1966	12,924	. Vidjongtius	www.kalbe.co.id

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products.

PT Kalbe Farma Tbk. Fundamentals Summary

How do Kalbe Farma's earnings and revenue compare to its market cap?
PTKF.Y fundamental statistics
Market cap	US$3.63b
Earnings (TTM)	US$190.21m
Revenue (TTM)	US$1.98b

19.1x

P/E Ratio

1.8x

P/S Ratio

Is PTKF.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTKF.Y income statement (TTM)
Revenue	Rp32.13t
Cost of Revenue	Rp19.91t
Gross Profit	Rp12.21t
Other Expenses	Rp9.13t
Earnings	Rp3.08t

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	66.74
Gross Margin	38.02%
Net Profit Margin	9.59%
Debt/Equity Ratio	3.0%

How did PTKF.Y perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

46%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 01:01
End of Day Share Price	2024/12/06 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Kalbe Farma Tbk. is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Helmy Kristanto	BNP Paribas Securities (Asia)
Swati Chopra	BofA Global Research
Jason Chandra	CGS International